The Metabolic Reset
GLP-1 receptor agonist fat loss — clinical-grade results
Semaglutide or tirzepatide-based fat loss protocol producing clinically documented weight reductions of 15–22%+ through powerful appetite suppression and metabolic optimization.
Duration
24 weeks
Difficulty
Beginner
Compounds
2 Peptides
Primary Goal
Significant fat loss and metabolic improvement
Why This Stack Works
The Metabolic Reset is the peptide protocol for significant, clinically-grounded fat loss. It is built around tirzepatide — the compound behind Mounjaro and Zepbound — which represents the current peak of GLP-1-class fat loss efficacy with its dual GLP-1/GIP receptor activation and 22.5% average weight reduction in clinical trials.
The protocol addresses the most important practical obstacle to GLP-1-class compound success: GI tolerability during dose escalation. The standard dose escalation approach (starting at 2.5mg weekly and increasing every 4 weeks) minimizes side effects for most users, but BPC-157 as a concurrent gut optimization compound dramatically reduces the nausea and GI discomfort that causes protocol abandonment. The result is a significantly more manageable escalation process and faster achievement of therapeutic dosing ranges.
Fat loss with tirzepatide occurs through multiple mechanisms simultaneously: appetite suppression via hypothalamic GLP-1 receptor activation, slowed gastric emptying extending meal satiety, improved peripheral insulin sensitivity reducing fat storage signals, and potential direct fat oxidation effects via GIP receptor activation in adipose tissue. The weight that is lost is predominantly fat — visceral fat in particular, which poses the greatest metabolic health risk and is the most resistant to diet and exercise alone.
For individuals who want a more aggressive protocol or have found semaglutide alone insufficient, Retatrutide (triple GLP-1/GIP/Glucagon agonist) can be substituted as the primary compound for the highest efficacy available — documented 24.2% weight reduction in Phase 2 trials.
The Synergy Mechanism
BPC-157 and tirzepatide work synergistically through their respective GI mechanisms. Tirzepatide's slowed gastric emptying and altered gut motility creates the GI environment most prone to side effects during dose escalation. BPC-157's anti-inflammatory, mucosal healing, and nitric oxide modulating effects directly address the gut tissue changes that cause these symptoms — reducing nausea, improving motility regulation, and healing any mucosal irritation that GLP-1 receptor activation produces. The result is better tolerability, faster dose progression, and fewer protocol interruptions due to side effects.
Compounds & Roles
Why It's In This Stack
Tirzepatide is the most effective single-compound fat loss peptide available through Apollo — demonstrated 22.5% average weight reduction at the highest dose in clinical trials, exceeding semaglutide's outcomes. Dual GLP-1 and GIP receptor activation produces both the powerful appetite suppression of GLP-1 agonism and the metabolic improvements of GIP activation. For those who have never used a GLP-1-class compound, tirzepatide delivers the most impressive fat loss outcomes available.
Why It's In This Stack
The most common side effects of tirzepatide and other GLP-1-class compounds are gastrointestinal: nausea, discomfort, and altered gut motility during dose escalation. BPC-157 directly addresses these through its profound gut-healing and anti-inflammatory effects. Running BPC-157 concurrently — especially during the first 8–12 weeks of dose escalation — significantly reduces GI side effects, improves tolerability, and allows for faster dose progression to therapeutic fat loss ranges.
Expected Timeline
Weeks 1–4
Escalation Phase 1
Tirzepatide at 2.5mg weekly. BPC-157 daily for GI support. Appetite reduction begins — most users notice meaningful hunger reduction within the first 1–2 weeks. Body weight reduction of 1–3% typical in this phase.
Weeks 5–12
Dose Progression
Escalating tirzepatide: 5mg (weeks 5–8), 7.5mg (weeks 9–12). Fat loss accelerates with each dose increase. Appetite suppression deepens. Visceral fat reduction becomes visible — particularly reduced abdominal circumference.
Weeks 13–20
Therapeutic Range
Tirzepatide at 10–15mg weekly. Peak fat loss rate. Most users find this phase produces the most dramatic visible body composition changes. BPC-157 can be reduced to intermittent use if GI tolerance is established.
Weeks 21–24
Consolidation
Maintaining therapeutic dose. Fat loss continues, pace may moderate. Focus on establishing nutritional habits that will maintain results long-term. Total body weight reduction of 15–22%+ achievable across the full protocol.
Who Is This Stack For?
Designed for anyone with significant excess body fat who wants clinical-grade fat loss outcomes. Ideal for those who have tried conventional diet and exercise protocols and encountered the metabolic adaptation that limits results, those with metabolic health concerns (insulin resistance, elevated triglycerides, high blood pressure), and those who want the most efficient path to substantial body fat reduction. Not suitable as a body composition "finisher" protocol — this is for those with meaningful fat loss goals.
Frequently Asked Questions
What is the difference between semaglutide and tirzepatide for this protocol?
Semaglutide activates only GLP-1 receptors and produces ~15% weight loss. Tirzepatide activates both GLP-1 and GIP receptors and produces ~22.5% weight loss at peak dosing. Tirzepatide is the recommended primary compound for this protocol due to superior efficacy. Semaglutide is a good starting point for those who prefer to begin with the simpler compound.
Why does this stack include BPC-157?
GLP-1-class compounds frequently cause GI side effects (nausea, bloating, discomfort) especially during dose escalation. BPC-157's gut-healing and anti-inflammatory effects directly reduce these side effects, improve tolerability, and prevent protocol abandonment. It is one of the most practical additions to any GLP-1 protocol.
Will I lose muscle mass on this protocol?
GLP-1-class compounds primarily mobilize fat rather than muscle. Adding CJC-1295/Ipamorelin to the stack preserves and builds lean mass while the fat loss occurs — creating a superior body composition outcome vs. fat loss alone.
Can I use retatrutide instead of tirzepatide?
Yes — retatrutide (triple GLP-1/GIP/Glucagon agonist) is the most potent fat loss compound available through Apollo, with 24.2% average weight reduction in Phase 2 trials. It requires a more gradual escalation protocol due to its potency. Substituting retatrutide for tirzepatide is appropriate for those seeking maximum efficacy.
Shop This Stack
Key Benefits
Expected Outcomes
Cycle Protocol
Continuous protocol: tirzepatide is used at maintenance dosing until target weight is achieved. Unlike cycle-based compounds, GLP-1-class peptides are typically used continuously for the duration of the research period. After achieving target weight, dose can be tapered to the lowest dose that maintains outcomes. BPC-157 cycles 8 weeks on, 4 weeks off within the larger protocol.
More Protocols
View AllThe Looks Max Stack
Addresses the biological pillars of physical appearance: skin collagen architecture, anti-wrinkle neuromuscular signaling, tissue repair, and cellular longevity.
The Body Sculptor
Dual growth hormone axis stimulation combined with direct IGF-1 delivery — the most comprehensive natural body composition transformation protocol.
The Wolverine Stack
Combines the two most powerful tissue repair peptides for comprehensive local and systemic healing — enabling training frequency otherwise unattainable.
